CD19 and precursor B-cell acute lymphoblastic leukemia: Rapid translation of BAFF-R CAR T-cell therapy to clinical application is warranted because it is a potentially promising immunotherapy, especially for antigen-loss r/r B-ALL following CD19-targeted treatments.